Payer Evidence Requirements: What Coverage Decisions Actually Demand

← Back to All Insights

Sponsors often generate the clinical evidence FDA requires and then find that payers want something different. The evidence that clears or approves a product is not always the evidence that gets it covered, and the gap is easier to see while a pivotal study is still being designed than after it reads out.

FDA evaluates safety and effectiveness. Payers ask whether a product improves health outcomes for the people they cover compared with the alternatives, and some also weigh cost.

The Three Evidence Questions Payers Ask

Does the technology improve health outcomes compared with the current standard of care? In which patient population? And, for payers that consider cost, what does it cost relative to the benefit? FDA's findings on safety and effectiveness are necessary but don't answer all three. Comparative effectiveness data, well-defined populations and, where relevant, economic analysis fill the gap.

Medicare and Cost

Medicare covers items and services that are reasonable and necessary, and federal law bars the Secretary from using a dollars-per-quality-adjusted-life-year threshold to determine Medicare coverage, reimbursement or incentive programs (42 U.S.C. § 1320e-1(e)). Commercial payers are not bound by that provision, and how they use cost information varies.

ICER and the Comparative Effectiveness Frame

The Institute for Clinical and Economic Review (ICER) publishes evidence reports that compare treatments on clinical benefit and cost, using measures such as the quality-adjusted life year (QALY) and the equal value of life years (evLY). Whether or not ICER ever reviews a given product, a useful test for any evidence package is whether it would hold up to that kind of comparative review.

Medicare's Coverage Pathway for Breakthrough Devices

For devices, CMS's Transitional Coverage for Emerging Technologies (TCET) pathway, finalized August 7, 2024, was set up as a voluntary route for up to five FDA-designated Breakthrough devices a year, using the national coverage determination and coverage with evidence development processes, with a goal of finalizing coverage within six months after FDA authorization. As of an August 11, 2026 notice, CMS has stopped taking new TCET candidates while it stands up RAPID, a proposed faster coverage pathway for Breakthrough Devices; see our article on RAPID.

Real-World Evidence in Coverage Decisions

Real-world evidence (RWE) can supplement trial data, particularly for expanded indications or continued coverage. For devices, FDA's final guidance on using RWE in regulatory decisions, announced December 18, 2025, replaced its 2017 guidance. Whether the audience is a regulator or a payer, quality decides how much RWE counts: identifiable patient populations, reliable outcome ascertainment, comparable control groups and pre-specified analysis plans.

Evidence Generation Strategy

An evidence plan built only for the FDA submission can leave payer questions unanswered. Plans that anticipate coverage often run several streams: the pivotal study for FDA, comparative effectiveness data for payers, an economic model where cost matters, and post-approval real-world evidence. Each needs its own study design and operational capability.

Diligence Implications

For a medical device or therapeutics company, it is worth checking whether the evidence plan supports both the FDA decision and coverage. A pivotal study designed without comparative-effectiveness or cost questions in view can leave gaps that have to be filled after approval, when time and money are tighter.

Payer evidence requirements are specific and can be read in advance. The question for a diligence read is whether the company's evidence plan was built with them in view.